Login / Signup

Integrated proteogenomic characterization of medullary thyroid carcinoma.

Xiao ShiYaoting SunCenkai ShenYan ZhangRongliang ShiFan ZhangTian LiaoGuojun LvZhengcai ZhuLianghe JiaoPeng LiTiansheng XuNing QuNaisi HuangJiaqian HuTingting ZhangYanzi GuGuangqi QinHaixia GuanWeilin PuYuan LiXiang GengYan ZhangTongzhen ChenShenglin HuangZhikang ZhangShuting GeWu WangWeibo XuPengcheng YuZhongwu LuYulong WangLiang GuoYu WangTiannan GuoQinghai JiWenjun Wei
Published in: Cell discovery (2022)
Medullary thyroid carcinoma (MTC) is a rare neuroendocrine malignancy derived from parafollicular cells (C cells) of the thyroid. Here we presented a comprehensive multi-omics landscape of 102 MTCs through whole-exome sequencing, RNA sequencing, DNA methylation array, proteomic and phosphoproteomic profiling. Integrated analyses identified BRAF and NF1 as novel driver genes in addition to the well-characterized RET and RAS proto-oncogenes. Proteome-based stratification of MTCs revealed three molecularly heterogeneous subtypes named as: (1) Metabolic, (2) Basal and (3) Mesenchymal, which are distinct in genetic drivers, epigenetic modification profiles, clinicopathologic factors and clinical outcomes. Furthermore, we explored putative therapeutic targets of each proteomic subtype, and found that two tenascin family members TNC/TNXB might serve as potential prognostic biomarkers for MTC. Collectively, our study expands the knowledge of MTC biology and therapeutic vulnerabilities, which may serve as an important resource for future investigation on this malignancy.
Keyphrases